Day Two | Thursday, August 5 | All Times Shown Are EDT

8:55 am Chairperson’s Opening Remarks

Analyzing the Approaches to Formulating Skin Microbiome Products

9:00 am Clinical Data of Real Topical Microbiome Skincare Products for Problematic Skin Like Acne & Atopic Dermatitis


  • Showcasing the latest clinical data from a topical probiotic product aimed at acne and atopic dermatitis
  • A discussion around the targeted screening of bacteria for skincare application, manufacturing, and formulation

9:30 am Panel Discussion – Considerations When Formulating Skin Microbiome Products


  • What different approaches are available?
  • How does the process differ between different formulation strategies?
  • How do you incorporate the opinions of consumers into your choice of formulation?

Developing Active Ingredients for Cosmetic Application

10:10 am A Polylysine Dendrigraft Able to Balance Acneic & Non Acneic Strains of Cutibacterium acnes to Prevent Acne and Skin Imperfections

  • Joan Attia Global R&D Director , IFF - Lucas Meyer Cosmetics


  • A green polylysine dendigraft, the Dendrimer (G2), able to rebalance acneic and non acneic strains of C. acnes to protects skin from inflammation, sebum secretion and acne

10:40 am Speed Networking

Assessing the Use of Bacteriophages as a Skin Microbiome Modulator

11:10 am Topical Phage Products For Acne-Prone Skin & Atopic Dermatitis: Clinical & Pre-Clinical Insights


  •  BiomX is a world leader in developing phage therapies that target and kill pathogenic bacteria in chronic indications
  • BX001 is a topical gel formulation of a cocktail of naturally-occurring phage targeting C. acnes. BX001 demonstrated in a phase 1 cosmetic clinical study statistically significant reduction of C. acnes levels compared to placebo
  • BiomX is also developing a topical phage treatment for atopic dermatitis targeting S. Aureus, a bacteria thought to contribute to development and exacerbation of inflammation in atopic dermatitis

11:40 am How Phage Capsids Can Be Engineered for Gene Therapy of the Microbiome


  • Different type of microbiome modulation strategies
  • Sequence-specific CRISPR-based antimicrobials

12:10 pm Precise Microbiome Editing: A Pathway to Mechanistic & Clinical Insights Into the Microbiome


  • The study of the microbiome brings us to the cusp of a new age of cellular therapies
  • Phyla’s novel approach to ‘kill and replace’ pathogens with high specificity offers a different paradigm to treat chronic bacterial diseases
  • Clinical data supports this approach for acne, and opens tantalizing possibilities for a more sophisticated tool for tackling other chronic bacterial diseases

12:40 pm Networking Lunch

Pre-Clinical Development of Microbial Consortia

1:30 pm Restoring Healthy Skin Ecology with Microbial Ensembles


  • Beyond single beneficial strains, interactions among skin microbes underpin skin health, so effective microbial therapeutics must restore healthy microbial interactions
  • Concerto Biosciences’ novel ultra-high-throughput screening technology constructs millions of microbial communities, among which we identify Microbial Ensembles—optimal, therapeutic combinations of microbes
  • By virtue of our rigorous discovery process, Concerto Biosciences’ Microbial Ensembles will effectively treat skin diseases

Overcoming Biofilm Formation

2:00 pm Biofilm Production & Inflammatory Skin Molecules Support the Growth & Persistence of Cutibacterium acnes in Acne Vulgaris


  • Microbiota analysis showed a significantly higher relative abundance of C.acnes in inflammatory compared with non-inflammatory acne lesions, unaffected skin, and the skin of healthy subjects
  • C.acnes strains isolated from acne patients were significantly more efficient in biofilm production than those isolated from healthy subjects’ skin
  • The level of cutaneous interleukin-a, and vascular endotherlial growth factor (VEGF) were significantly higher in the skin of of acne patients compared to controlled subjects. The presence of both IL-1a and VEGF selectively promoted a concentration-dependent increase of C. acnes growth in vitro

2:30 pm Open Innovation in Skin Microbiome/Biofilms R&D: Translation of Academic Research to Address Industry Needs


  • Discussing the journey of NBIC – a UKRI funded innovation hub facilitating research excellence, innovation capacity and industry engagement in the broad field of biofilms and microbiome within the personal care industry
  • NBIC helps academics to better understand the commercial environment, encourage new start-ups and take advantage of new, diverse market opportunities

3:00 pm Panel Discussion – Developing an Evidence Based Approach to Microbiome Research


  • How does the industry ensure it keeps its scientific integrity?
  • In what ways can more data be collected to help with substantiating claims?
  • When we speak of healthy skincare, what does that mean and how do you measure it?

3:30 pm End of Day Two